How to Differentiate Myopic Choroidal Neovascularization, Idiopathic Multifocal Choroiditis, and Punctate Inner Choroidopathy Using Clinical and Multimodal Imaging Findings

2017 ◽  
Vol 48 (3) ◽  
pp. 196-201 ◽  
Author(s):  
Rosa Dolz-Marco ◽  
Howard F. Fine ◽  
K. Bailey Freund
2020 ◽  
pp. 112067212091762
Author(s):  
Chiara Giuffrè ◽  
Alessandro Marchese ◽  
Giovanni Fogliato ◽  
Elisabetta Miserocchi ◽  
Giulio Maria Modorati ◽  
...  

Introduction: To investigate choroidal thickness changes related to the clinical activity of inflammatory choroidal neovascularization in punctate inner choroidopathy/multifocal choroiditis as compared to myopic choroidal neovascularization. Materials and methods: Consecutive inflammatory choroidal neovascularization secondary to punctate inner choroidopathy/multifocal choroiditis, and myopic choroidal neovascularization were retrospectively reviewed. By means of enhanced-depth imaging optical coherence tomography, choroidal thickness was assessed at the same location before choroidal neovascularization development, at choroidal neovascularization onset (baseline), and after treatment. Results: Eleven eyes with inflammatory choroidal neovascularization and 11 eyes with myopic choroidal neovascularization were analyzed. Choroidal thickness beneath inflammatory choroidal neovascularization significantly increased at baseline and decreased after therapy (“Sponge sign”), reaching preclinical values. In particular, mean choroidal thickness under inflammatory choroidal neovascularization was 145 ± 85 µm at the preclinical stage, increased to 210 ± 103 µm at baseline (p = 0.006), and decreased to 136 ± 87 µm after treatment (p = 0.017). Conversely, no significant choroidal thickness changes were disclosed in myopic choroidal neovascularization eyes, under any location. Conclusion: Optical coherence tomography–based choroidal thickness evaluation may represent an additional useful tool to monitor inflammatory choroidal neovascularization activity. Moreover, choroidal thickness under choroidal neovascularizations could be used to discriminate the origin of choroidal neovascular membrane, either inflammatory or myopic, in doubtful cases and guide the therapeutic management.


2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Mousavi MirNaghi ◽  
Shoeibi Nasser ◽  
Hosseini SeyedehMaryam ◽  
Saadat Targhi Ali

Choroidal osteoma has been reported to be unilateral in approximately 80% of cases diagnosed with this condition. Herein we report the clinical characteristics and multimodal imaging findings in a rare case of bilateral multifocal choroidal osteoma. A 32-year-old female presented with decreased visual acuity (VA) in the right eye (20/100), though she had normal VA (20/20) in the left eye. Ophthalmoscopy and multimodal imaging investigation revealed bilateral multifocal choroidal osteoma complicated by choroidal neovascularization (CNV) in the right eye. Following three injections of intravitreal bevacizumab (IVB) for CNV in the right eye, VA improved to 20/40.


2016 ◽  
Vol Volume 10 ◽  
pp. 1749-1757 ◽  
Author(s):  
Paolo Milani ◽  
Amedeo Massacesi ◽  
Stefania Moschini ◽  
Marco Setaccioli ◽  
Ennio Bulone ◽  
...  

2017 ◽  
Vol 27 (6) ◽  
pp. e184-e186 ◽  
Author(s):  
Giorgia C. Albertini ◽  
Eleonora Corbelli ◽  
Maurizio Battaglia Parodi ◽  
Francesco Bandello

Purpose To describe a case of bilateral choroidal neovascularization (CNV) in multifocal choroiditis (MFC) associated with dabrafenib and trametinib chemotherapy for metastatic melanoma. Case We present a case of a 57-year-old man with MFC who underwent combination therapy with dabrafenib plus trametinib for metastatic melanoma. The patient presented to our ophthalmology department complaining of bilateral vision loss of 2 days’ duration. He underwent multimodal imaging showing a MFC reactivation complicated by bilateral CNV. The patient underwent 3 ranibizumab injections in the right eye and 7 ranibizumab injections in the left eye. Anatomical and functional improvement has been observed. Conclusions This report emphasizes the importance of strict ophthalmologic follow-up in patients with metastatic melanoma treated with dabrafenib plus trametinib since rare severe ocular toxicities can occur, especially in patients with a history of uveitis.


Retina ◽  
2013 ◽  
Vol 33 (7) ◽  
pp. 1315-1324 ◽  
Author(s):  
Richard F. Spaide ◽  
Naomi Goldberg ◽  
K. Bailey Freund

Sign in / Sign up

Export Citation Format

Share Document